Recovering scientist turned early stage VC A biotech optimist fighting gravity

Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations
April 11, 2019

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Every morning before I go to work, I review my calendar for the day. This gets me into the

Leave a comment

Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that

Leave a comment

Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up
April 1, 2019

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the inflammasome, a key innate immune node whose pathologic chronic activation is associated with

Leave a comment

Arteaus’ Final Chapter: Monetization Of The Emgality Royalties
April 1, 2019

Back in September 2018, the FDA approved Lilly’s Emgality, an anti-CGRP antibody therapy, for the preventative treatment of episodic and chronic migraine. Arteaus Therapeutics, a biotech company founded by Atlas Venture in 2011, played a critical role in Emgality’s early

Leave a comment

If You Build It, Will They Come? Addressing The Value Equation
March 12, 2019

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Over my experience building several therapeutics companies, I’ve sometimes observed a Field of Dreams approach to therapeutics:

Leave a comment

Sharing The Adaptive Ski Experience With The Biotech Community
February 25, 2019

JB Harvey broke his personal record earlier this winter by skiing over 22 trails in a single day at Loon Mountain. It was an awesome day. And 22 runs would be a huge day for anyone, but it was particularly

Leave a comment

Keep Calm and Carry On: How to Survive an FDA Inspection
February 21, 2019

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. It was apparently random, although I secretly suspect it was karmic punishment for my lack of imagination in writing the

Leave a comment

Leave A Ladder Down
February 19, 2019

This post was written by Ros Deegan, President and CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In May 2007, I trekked to Everest Base Camp in Nepal. Situated at an altitude of over

Leave a comment

All A-Board
February 14, 2019

This blog is written by Samantha Truex, Atlas EIR and CEO of a stealth-stage biotech, as part of the From The Trenches feature of LifeSciVC. In a 2014 analysis  of biotech boards and a reprise analysis in 2016, Bruce Booth

Leave a comment

Our Year In Review: Annual Talk On Macro, Biotech, and Atlas
February 12, 2019

At the end of every year, we host both our Atlas Venture Annual Meeting for our fund investors (Limited Partners) and our Atlas Retreat for senior industry executives.  As a kickoff for these two meetings, we typically open with a

Leave a comment

Biotech Insider Stock Sales: Peer Benchmarks And Guidelines
February 6, 2019

Over the past six years, the biotech sector has experienced an incredible run of IPOs, reflecting the longest and largest “open window” for new offerings. Much has been written about post-IPO performance here and elsewhere, but there’s been little discussion

Leave a comment

Predicting The Next Dominoes to Fall in 2019
January 31, 2019

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the

Leave a comment